よむ、つかう、まなぶ。
06【参考資料１】Interim statement on the composition of current COVID19 vaccines World Health Organization 17 June 2022 (5 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_26922.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会（第33回 7／22）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
1
have already received a primary vaccine series may elicit greater breadth in the
2
immune response. In contrast, an Omicron-specific monovalent vaccine product
3
as a standalone formulation for the primary series is not advised as it is not yet
4
known whether Omicron-specific vaccines will offer similar cross-reactive
5
immunity and cross-protection from severe illness caused by other VOCs in
6
unprimed individuals as the index virus-based vaccines have done.
7
8
Although bi- or multivalent products have yet to be approved by regulatory
9
authorities, vaccines containing index virus and Omicron in a single product may
10
be able to achieve similar outcomes as the proposed sequential approach. However,
11
at this time, only limited data are available to assess whether the cross-reactive
12
immune responses in humans using an Omicron-containing bi/multivalent
13
product will be equivalent to those elicited with a sequential vaccine approach.
14
15
The TAG-CO-VAC recognizes that the inclusion of Omicron, as the most
16
antigenically distinct VOC to date, in a variant-specific formulation and
17
administered as a booster dose, does not preclude the consideration of other
18
variant-specific formulations by regulatory authorities. The key additional
19
objective of modified COVID-19 vaccine formulations is to achieve breadth of
20
cross-reactive immunity to previous, currently circulating and/or emerging
21
variants.
22
23
Conclusion
24
The use of currently licensed vaccines based on the index virus confers high levels
25
of protection against severe disease outcomes for all variants, including Omicron
26
with a booster dose. As such, the continued use of currently licensed vaccines for
27
primary vaccination and as a booster dose is appropriate to achieve the primary
28
goals of COVID-19 vaccination. Given the uncertainties of the genetic and
29
antigenic characteristics of future SARS-CoV-2 variants, it may be prudent to
30
pursue an additional objective of COVID-19 vaccination of achieving a greater
31
breadth in the antibody response against circulating and emerging variants, while
32
retaining protection against severe disease and death. In this context, available
5
have already received a primary vaccine series may elicit greater breadth in the
2
immune response. In contrast, an Omicron-specific monovalent vaccine product
3
as a standalone formulation for the primary series is not advised as it is not yet
4
known whether Omicron-specific vaccines will offer similar cross-reactive
5
immunity and cross-protection from severe illness caused by other VOCs in
6
unprimed individuals as the index virus-based vaccines have done.
7
8
Although bi- or multivalent products have yet to be approved by regulatory
9
authorities, vaccines containing index virus and Omicron in a single product may
10
be able to achieve similar outcomes as the proposed sequential approach. However,
11
at this time, only limited data are available to assess whether the cross-reactive
12
immune responses in humans using an Omicron-containing bi/multivalent
13
product will be equivalent to those elicited with a sequential vaccine approach.
14
15
The TAG-CO-VAC recognizes that the inclusion of Omicron, as the most
16
antigenically distinct VOC to date, in a variant-specific formulation and
17
administered as a booster dose, does not preclude the consideration of other
18
variant-specific formulations by regulatory authorities. The key additional
19
objective of modified COVID-19 vaccine formulations is to achieve breadth of
20
cross-reactive immunity to previous, currently circulating and/or emerging
21
variants.
22
23
Conclusion
24
The use of currently licensed vaccines based on the index virus confers high levels
25
of protection against severe disease outcomes for all variants, including Omicron
26
with a booster dose. As such, the continued use of currently licensed vaccines for
27
primary vaccination and as a booster dose is appropriate to achieve the primary
28
goals of COVID-19 vaccination. Given the uncertainties of the genetic and
29
antigenic characteristics of future SARS-CoV-2 variants, it may be prudent to
30
pursue an additional objective of COVID-19 vaccination of achieving a greater
31
breadth in the antibody response against circulating and emerging variants, while
32
retaining protection against severe disease and death. In this context, available
5